| Nov 11 |
Ainos Announces IRB Approval for Sjögren’s Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
|
| Nov 9 |
Ainos Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.73 loss in 3Q 2023)
|
| Nov 8 |
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
|
| Nov 7 |
Ainos reports Q3 results
|
| Nov 6 |
Ainos Reports Third Quarter 2024 Financial Results
|
| Oct 28 |
Ainos Expands Patent Portfolio With Strategic Shareholder’s Cutting-Edge Technology Assets
|
| Oct 7 |
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
|
| Sep 20 |
Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts
|
| Sep 17 |
Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
|
| Aug 27 |
Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference
|
